Lung Neoplasms Clinical Trial
The purpose of this study is to show that dogs are able to detect cancer in sweat samples. This potentially would be the base for developing a new efficient, non invasive and inexpensive diagnosis tool of lung cancer.
Among all cancers which harm the population, lung cancer is the most lethal type,
responsible for 1.3 million deaths per year worldwide, for 28% of all cancer deaths.The 5
year survival rates are low, only 15%.
Diagnosis and treatment of lung cancer in its early stages could increase the
5-year-survival rate by 3-4 fold with a potential for cure. Therefore, efforts are being
made to develop new sensitive specified screening tools for detecting lung cancer at its'
earliest stages.
A new emerging strategy for early detection of lung cancer is based on the recognition of
the tumors metabolic signature, on the identification of specific biomarkers for the
disease, such as the volatile organic compounds (VOC). Research has demonstrated that these
compounds are released from the cancerous tissue from the early stages of the disease, and
can be found in different bodily secretions.
The subjects, lung cancer patients and chronic obstructive pulmonary disease (COPD)
patients, would be given cotton T-shirts with instructions to wear them without previously
applying deodorant or any other similar personal hygiene products. Then, the shirts would be
collected and 8 pieces (size:1cm*3cm from the armpit areas) would be cut from each one.
Dogs for this study would be trained by the "Dogs for People" association. In the initial
stage, 40 mixed breed dogs and 3-4 Springer spaniels would be exposed to sweat sample
collected from cancer patients in order to get them acquainted with the scent. Then, it
would be demanded of them to locate boxes containing T-shirt sample taken from cancer
patients, from decoy boxes holding naïve T-shirts. Every sequence will include 4 boxes with
a different ratio between the specimens(each time a different number of boxes will contain
samples taken from cancer patients, 0,1,2,3 or 4 when the rest of the boxes would contain
naïve T-shirts). The dogs would mark the specimen by sitting next to each relevant box (they
will ignore the decoy boxes after sniffing them and identifying them as irrelevant).
The most prominent 8-9 dogs would continue to the experiment phase. Each training course
would last for 5-10 minutes or for 8 successful identifications, depending on the training
dog needs. Dogs would be rewarded with a treat (a dog biscuit) or with play time, depending
on the dogs' nature.
In the experimental phase, the decoy boxes would hold sweat samples collected from COPD
patients instead of naïve T-shirts. The dogs would be asked to locate boxes containing the
T-shirt sample taken from the lung cancer patients, from the decoy boxes. Every sequence
will include 4 boxes with a different ratio between the specimens (each time a different
number of boxes will contain samples taken from cancer patients, 0,1,2,3 or 4 when the rest
of the boxes would contain samples collected from COPD patients). The dogs would mark the
specimen by sitting next to each relevant box (they will ignore the decoy boxes after
sniffing them and identifying them as irrelevant).
The trainer would be oblivious to the targets' location.
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03357094 -
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
|
N/A | |
| Recruiting |
NCT05543954 -
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
|
Early Phase 1 | |
| Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
| Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
N/A | |
| Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
| Completed |
NCT02531737 -
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02284633 -
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
||
| Completed |
NCT02106143 -
RejuvenAirâ„¢ System Lobectomy Safety and Histology Study
|
N/A | |
| Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
| Enrolling by invitation |
NCT01687647 -
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
|
Phase 3 | |
| Terminated |
NCT00356525 -
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
|
Phase 2 | |
| Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00351962 -
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
|
N/A | |
| Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT00090701 -
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|